To avoid overdiagnosis and overtreatment of prostate cancer, we need to be smarter about how we use prostate-specific antigen (PSA) tests. Recommendations for screening have already begun to change. Learn more.
Finding prostate tumors that need to be treated versus those that aren’t dangerous isn’t easy. A new technology called fusion guided biopsy combines MRI and ultrasound. The result: a better screening tool.
Eric Klein, MD, dispels common myths about prostate cancer, including misconceptions about prostate-specific-antigen (PSA) testing and prostate surgery.
Cleveland Clinic’s expanding kidney transplant program, streamlined waiting times and other innovations are improving access to this life-changing surgery.
Much confusion exists about the right way to screen, diagnose and treat prostate cancer. It’s time to refine our screening approach to curb overdiagnosis and overtreatment of this common cancer.
Men over 40 should start seeing a urologist regularly to stay proactive with their prostate, urinary and sexual health. Urologist Eric Klein, MD, talks about why it’s a good idea.
A new genetic-based test, the Oncotype DX prostate cancer test, will allow more men with low-risk prostate cancer to choose active surveillance – sparing them unnecessary treatment and life-altering side effects.
If you’ve been diagnosed with prostate cancer, don’t assume that surgery or radiation therapy is in your future. First, talk to your doctor. While surgery or radiation is best for some aggressive cancers, it’s not always necessary.
For the first time, our urology and nephrology programs are each ranked No. 1 in the United States by U.S. News & World Report in the publication’s “Best Hospitals 2013” rankings. We are both delighted and humbled by this recognition.